Research Studies

Study Title

Neuraltus NP001 Trial (Safety and Efficacy Study of NP001 in Patients With ALS and Systemic Inflammation)

Enrollment Status

Completed

Principal Investigators

Site-PI: Michael Benatar, MD, PhD

Study Type

Drug Trial

Goals

This is a 6 month randomized, double-blind, placebo-controlled study of NP001 in subjects with ALS and evidence of elevated systemic inflammation.

Enrolling

ALS patients

Eligibility

Click to Expand

Study Involvement

Click to Expand

Subjects will be allocated (1:1) to NP001 and placebo.
Drug or placebo will be given by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6.

Contact

Links

Primary Funding Source

Neuraltus Pharmaceuticals, Inc

Related Publications

Click to Expand

No items found

Related Presentations & Lectures

Click to Expand

No items found